Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (DE:J7Z)
FRANKFURT:J7Z
J7Z Stock Chart & Stats
Day’s Range― - ―
52-Week Range€92.40 - €139.55
Previous CloseN/A
Volume0.00
Average Volume (3M)28.00
Market Cap
$8.40B
Enterprise Value€10.62B
Total Cash (Recent Filing)$309.62M
Total Debt (Recent Filing)$1.60B
Price to Earnings (P/E)17.0
Beta0.38
Next Earnings
Apr 30, 2025EPS Estimate
4.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.09
Shares Outstanding60,732,480
10 Day Avg. Volume54
30 Day Avg. Volume28
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)N/A
Price to Sales (P/S)2.14
Price to Cash Flow (P/CF)5.50
P/FCF Ratio5.50
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda7.33
Forecast
1Y Price Target
€182.59Price Target Upside32.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Earnings And Financial PerformanceJazz Pharmaceuticals reported higher-than-expected revenue and earnings per share, indicating strong financial performance.
Market Position And GrowthXywav remains the company's primary revenue driver, with net product sales of $401M, as a result of net patient adds and increasing market share in narcolepsy and idiopathic hypersomnia.
Bears Say
Strategic FocusManagement’s increasing focus on oncology despite most of the revenue and growth continuing to stem from sleep and epilepsy presents a strategic head-scratcher.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.30% Insiders
29.59% Mutual Funds
34.94% Other Institutional Investors
4.71% Public Companies and Individual Investors
J7Z FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was €92.40 and its highest was €139.55 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $8.40B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Apr 30, 2025 which is in 57 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported €6.334 earnings per share for the quarter, beating the consensus estimate of €5.577 by €0.757.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 4.66.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,732,480 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of €6.334 in its last earnings report, beating expectations of €5.577. Following the earnings report the stock price went up 3.962%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:J7Z
---
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€182.59 (32.60% Upside)
€182.59 (32.60% Upside)
Blogger Sentiment
Bullish
DE:J7Z Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.66%
12-Months-Change
Fundamentals
Return on Equity
14.31%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
J7Z Company Deck
---
J7Z Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record revenues, successful product launches, and strong sales growth for key products like Epidiolex. However, challenges such as the impact of pediatric protocol changes on Rylaze and potential revenue erosion from upcoming generic competition were noted. The company demonstrated financial strength by reducing debt and maintaining strategic flexibility.Read More>---
J7Z Stock 12 Month Forecast
Average Price Target
€182.59
▲(32.60% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Heron Therapeutics
―
SAGE Therapeutics
―
Best Analysts Covering J7Z
1 Year
1 Year Success Rate
19/27 ratings generated profit
1 Year Average Return
+10.87%
reiterated a buy rating 6 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 70.37% of your transactions generating a profit, with an average return of +10.87% per trade.
---